haloquinone: from Streptomyces venezuelae ssp. xanthophaeus; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 133561 |
| MeSH ID | M0104618 |
| Synonym |
|---|
| 3-acetyl-1,8-dihydroxy-2-methyl-9,10-phenanthrenequinone |
| haloquinone |
| 9,10-phenanthrenedione, 3-acetyl-1,8-dihydroxy-2-methyl- |
| 80902-01-8 |
| 3-acetyl-1,8-dihydroxy-2-methylphenanthrene-9,10-dione |
| DTXSID50230779 |
| nsc789947 |
| nsc-789947 |
Haloquinones (XQs) are a group of carcinogenic intermediates of the haloaromatic environmental pollutants and newly identified chlorination disinfection byproducts.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Haloquinones (XQs) are a group of carcinogenic intermediates of the haloaromatic environmental pollutants and newly identified chlorination disinfection byproducts (DBPs) in drinking water. " | ( Mechanistic Study on Oxidative DNA Damage and Modifications by Haloquinoid Carcinogenic Intermediates and Disinfection Byproducts. Huang, CH; Mao, L; Shao, J; Tang, M; Zhu, BZ, 2021) | 2.06 |
| Excerpt | Relevance | Reference |
|---|---|---|
| "Three simple and sensitive spectrophotometric methods were developed and validated for determination of the hydrochloride salts of fluoxetine, sertraline, and paroxetine in their pharmaceutical dosage forms." | ( Development and validation of spectrophotometric methods for determination of fluoxetine, sertraline, and paroxetine in pharmaceutical dosage forms. Darwish, IA, ) | 0.13 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||